Hyperliquid's crude oil contract 24-hour total trading volume exceeds $550 million, Nasdaq 100 contract trading volume reaches $130 million
BlockBeats news, on March 16, according to HyperInsight monitoring, in the past 24 hours, the trading volume of CL (WTI crude oil mapping contract) on Hyperliquid exceeded $400 millions, second only to BTC's $1.57 billions and ETH's $810 millions, and twice the trading volume of SOL contracts at $200 millions. In addition, BRENTOIL (Brent crude oil mapping contract) trading volume exceeded $147 millions, both oil contracts were actively traded, with the total 24-hour crude oil contract trading volume surpassing $550 millions.
Additionally, on Hyperliquid, XYZ100 (Nasdaq 100 mapping contract) trading volume reached $130 millions, ranking seventh; SILVER (silver mapping contract) trading volume was $113 millions, ranking eighth; GOLD (gold mapping contract) trading volume was $48 millions, ranking eleventh.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley senior bond investor turns bullish on US Treasuries for the first time in ten years
US Stock Movement | SuperX AI Technology (SUPX.US) once fell more than 2.5%, hitting an intraday low of $6.46
SuperX AI Technology's stock price declined, falling more than 2.5% at one point.
BUZZ-Pacira BioSciences participated in a Viatris acquisition deal worth 1.65 billions dollars
Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)
Crypto prices
More
